Combination contains two medicines: Levosulpiride and Rabeprazole. Levosulpiride works on the upper digestive tract to increase the peristaltic movement by releasing acetylcholine (a chemical messenger), allowing the food to move more easily through the stomach and prevents reflux. Rabeprazole is categorised as proton pump inhibitor (PPI) that stops gastric acid secretion in the stomach that provide relief from acid-related indigestion and heartburn.
Gastroesophageal reflux disease (acid reflux)
Intestinal ulcers
Irritable bowel syndrome
Helicobacter Pylori (H. Pylori) Infection
Levosulpride is a dopamine D2-receptor antagonist. Levosulpiride acts more selectively on dopamine D2 antagonist. Sulpiride does not effects the levels of norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.
Rabeprazole decreases gastric acid production. Rabeprazole may also be used with other antibiotics in H. pylori infection along that are associated with gastric ulcers. Rabeprazole inhibits proton pump irreversibly and is very selective and hence suppresses gastric acid secretion by particularly inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells.
Levosulpride is absorbed slowly from GIT with only25-30% bioavailability.
Rabeprazole is well orally absorbed from GIT and the bioavailability ranges about 52%. Rabeprazole shows 96.3% of plasma protein binding and is extensively metabolised in liver. Approximately 90% of the drug was eliminated in the urine and the half-life is 1-2 hours in plasma.
Diarrhea
Stomach pain
Flatulence
Dryness in mouth
Dizziness
Headache
Carefully use in patients with renal and hepatic impairment
Hypersensitivity can occur in patient with phaeochromocytoma
Systemic lupus erythematosus
| Rabeprazole sodium IP | 20 mg |
| Levosulpride(as sustained release pellets ) | 75 mg |